Sign inJoin waitlistJoin the waitlist

Aaron Mansfield

Professor of Oncology · Mayo Clinic College of Medicine and Science

Credentials: · · · ·

History

Mayo Clinic College of Medicine and Science
Present

Hematology and Medical Oncology
Mayo Clinic College of Medicine and Science
2009–2012
Internal Medicine
Mayo Clinic College of Medicine and Science
2006–2009
University of California, Irvine School of Medicine
2002–2006

Research

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
New England Journal of Medicine · 2018 · 2,932 citations
Detection and localization of surgically resectable cancers with a multi-analyte blood test
Science · 2018 · 2,144 citations
First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial
The Lancet · 2021 · 999 citations

Tobias Peikert
26 papers
Haidong Dong
24 papers · 1 as a fellow
Svetomir Markovic
23 papers
Anja Roden
20 papers
Marie Aubry
18 papers
Mitesh Borad
18 papers
Sean Park
18 papers
Alex Adjei
17 papers
Julian Molina
16 papers
Konstantinos Leventakos
16 papers · 7 as a resident
Roxana Dronca
16 papers
Dennis Wigle
14 papers

Grants

Mayo Clinic Network Lead Academic Participating Site
National Cancer Institute · UG1
PI · $3.5M · Mayo Clinic Rochester
2019–2032
Rapid, Simple, and Ultrasensitive Quantitation of KRAS ctDNA at the Point of Care Using CRISPR/Cas Amplification and Digital Resolution Biosensor Microscopy
National Cancer Institute · R33
PI · $1M · University of Illinois at Urbana-Champaign
2023–2027
Blood-Based Biomarker of Therapeutic Efficacy for Mesothelioma
National Cancer Institute · R21
Contact PI · $408.8K · Mayo Clinic Rochester
2020–2024

Clinical trials

Examining Blood and Tissue Samples to Identify Diagnostic Markers in Patients With Metastatic Cancer Undergoing Tumor Removal
Principal investigator · Recruiting
Mayo Clinic
2022–2031
Patient Derived Preclinical Models
Principal investigator · Recruiting
Mayo Clinic
2022–2028
Chemotherapy With or Without Immunotherapy for Peritoneal Mesothelioma
Principal investigator · Recruiting · Phase 2
National Cancer Institute (NCI)
2022–2027
Pembrolizumab With or Without Anetumab Ravtansine in Treating Patients With Mesothelin-Positive Pleural Mesothelioma
Principal investigator · Active not recruiting · Phase 1, Phase 2
National Cancer Institute (NCI)
2018–2027